Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study

To see complete record on, please visit this link

Id: NCT02974010

Organisation Name: NeuroRx, Inc.

Overal Status: Completed

Start Date: January 15, 2018

Last Update: May 25, 2021

Lead Sponsor: NeuroRx, Inc.

Brief Summary: NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or 5) or Behavior (ASIB) in following initial stabilization. Patients with Severe Bipolar Depression and ASIB will be recruited in both inpatient and outpatient settings and, following informed consent, will be given an intravenous infusion of ketamine 0.5mg/kg over 40 minutes. Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone alone (the comparator group). This study is conducted as a feasibility study for a pivotal phase 2b/3 clinical trial and the primary outcomes for this phase 2 study were blood levels of NRX-101, in order to confirm pharmaco-kinetics with remission from depression, as measured by BISS-derived MADRS and relapse as secondary outcomes.

  • Bipolar Depression
  • Suicidal Ideas
  • Suicidal Ideation
  • Suicide, Attempted

Total execution time in seconds: 0.38799905776978